Neurophth Therapeutics
Signal active
Organization
Contact Information
Overview
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
About
Industries
Biotechnology, Life Science
Founded
2016
Employees
251-500
Headquarters locations
Asia
Social
N/A
Profile Resume
Neurophth Therapeutics headquartered in Asia, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $9.5B in funding across 40 round(s). With a team of 251-500 employees, Neurophth Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Neurophth Therapeutics, raised $97.1M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
12
Lead Investors
0
Total Funding Amount
$237.4M
Details
5
Neurophth Therapeutics has raised a total of $237.4M in funding over 5 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Seed | |||
| 2021 | Early Stage Venture | 61.9M | ||
| 2021 | Late Stage Venture | 60.0M | ||
| 2023 | Late Stage Venture | 97.1M |
Investors
Neurophth Therapeutics is funded by 36 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Wuhan optics valley health | - | FUNDING ROUND - Wuhan optics valley health | 97.1M |
| SDIC Fund Management | - | FUNDING ROUND - SDIC Fund Management | 97.1M |
| Neurophth Therapeutics | - | FUNDING ROUND - Neurophth Therapeutics | 97.1M |
| Zhejiang Silicon Paradise Asset Management Group | - | FUNDING ROUND - Zhejiang Silicon Paradise Asset Management Group | 97.1M |
Recent Activity
There is no recent news or activity for this profile.